About the Company
Israel had more companies listed in 2012 on the NASDAQ stock exchange than any country outside of the United States and China. As of 2011, some sixty Israeli companies are listed on the Nasdaq. 2000 was the year that saw the most new Israeli listings on the exchange – 33 companies. Through the years, many have been acquired, merged with other companies, privatized, or gone out of business. Since the 1980s, over 250 Israeli companies had an initial public offering on the Nasdaq. As of August 2017, one Israeli company was listed on the NASDAQ-100 index: Check Point Software.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ADCT News
ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript
ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript March 13, 2024 ADC Therapeutics SA misses on earnings ...
ADC Therapeutics SA ADCT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress
Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on ADC Therapeutics (ADCT – Research Report), retaining the price target ...
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.
ADC Therapeutics SA: ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the "Company") (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of ...
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings ...
Q4 2023 ADC Therapeutics SA Earnings Call
Q4 2023 ADC Therapeutics SA Earnings Call Q4 2023 ADC Therapeutics SA Earnings Call HOME MAIL NEWS FINANCE SPORT CELEBRITY STYLE WEATHER MORE... Yahoo Finance Sign in Mail Sign in to view your emails ...
ADCT ADC Therapeutics SA
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Q4 2023 ADC Therapeutics SA Earnings Call
Naureen Quibria; Analyst; Capital One Securities, Inc. Brian Cheng; Analyst; JPMorgan Chase & Co. Greg Renza; Analyst; RBC Capital Markets Kelly Shi; Analyst; Jefferies Financial Group Inc Welcome to ...
Loading the latest forecasts...